Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2018 - 2020)

Silence Therapeutics' Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at $33011.3 for Q4 2020.

  • On a quarterly basis, Non-Current Deferred Tax Liability rose 6.98% to $33011.3 in Q4 2020 year-over-year; TTM through Dec 2020 was $33011.3, a 6.98% increase, with the full-year FY2020 number at $32103.7, up 4.76% from a year prior.
  • Non-Current Deferred Tax Liability hit $33011.3 in Q4 2020 for Silence Therapeutics, up from $30857.4 in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for SLN hit a ceiling of $33011.3 in Q4 2020 and a floor of $16728.0 in Q4 2018.
  • Historically, Non-Current Deferred Tax Liability has averaged $26865.5 across 3 years, with a median of $30857.4 in 2019.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 84.47% in 2019 and later increased 6.98% in 2020.
  • Tracing SLN's Non-Current Deferred Tax Liability over 3 years: stood at $16728.0 in 2018, then surged by 84.47% to $30857.4 in 2019, then increased by 6.98% to $33011.3 in 2020.
  • Business Quant data shows Non-Current Deferred Tax Liability for SLN at $33011.3 in Q4 2020, $30857.4 in Q4 2019, and $16728.0 in Q4 2018.